We are live on ! Find out more
ADRX icon

ADARx Pharmaceuticals

62 hedge funds and large institutions have $1.53B invested in ADARx Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

71.88% more ownership

Funds ownership: 0% → 71.88% (+72%)

Holders
62
Holders Change
+62
Holders Change %
–
% of All Funds
0.76%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.05%
New
62
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ADRX Hedge Fund Activity: Q3 2026 in Review

62 of the 8,154 institutional investors tracked by Wall St. Rank reported a position in ADARx Pharmaceuticals (ADRX) for Q3 2026, worth a combined $1.53B.

Buyers outnumbered sellers: 62 funds opened new ADRX positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $484M.

  • 62 institutional investors held ADARx Pharmaceuticals (ADRX) as of Q3 2026, up from 0 in Q2 2026.
  • Funds reported $1.53B of ADARx Pharmaceuticals stock for Q3 2026.
  • 62 funds opened new ADARx Pharmaceuticals positions in Q3 2026 and 0 closed out, a net change of +62 holders.
  • The largest ADARx Pharmaceuticals buyer in Q3 2026 was OrbiMed, an estimated $484M added.

Based on aggregated 13F filings for Q3 2026.